

Antibodies for Licensing

Scientists at the Georg-August-University Göttingen generated many different monoclonal antibodies. We are looking for companies, who are interested in licensing these antibodies for selling them to industrial and scientific institutions or for developing advanced diagnostic tests and therapeutic solutions.

This unique collection comprises the listed clones:

Overview available clones for licensing page 1

Name	Clones	Host	Reactivity	Isotype	Application	References
Complementfactor B / Ba	P21/15	mouse	human	IgG2a/k	WB,E,IP	1-3
	M20/6	mouse	human	IgG1/k	WB,E,IP	1-4
	D22/3	mouse	human	IgG2b/k	WB,F,E	2-4
Complementfactor B / Bb	M13/12	mouse	human	IgG1/k	WB,E,IP	1-3
Complementfactor D	D10/4	mouse	human	IgG2a/k	WB,E	1-3; 5
	I8/1	mouse	human	IgG1/k	WB,E	1-3; 5
Complementfactor H	C18/3	mouse	human	IgG1/k	WB,E	1-3
	L20/3	mouse	human	Ig1/k	WB,E	1-3
Complementfactor H (402-His variant)	IH10	mouse	human	IgG1/k	IB, ELISA	not yet published
Complementfactor H (402-Tyr variant)	23F8	mouse	human	IgG1/k	IB, ELISA	not yet published
Activated C3 (iC3b/C3dg)	I3/15	mouse	human	Ig1/k	WB,E	1-3; 6; 7
C3a/C3a(desArg)/C3	K13/16	mouse	human	IgG1/k	WB,E,IP,FN	2; 3; 8-16
	D17/1	mouse	human	IgG1/k	WB,E	2; 3; 8; 10; 14-16
C5a/C5a(desArg)/C5	C17/5	mouse	human	IgG1/k	WB,E	2; 3; 8; 10; 14-16; 19
	G25/2	mouse	human	IgG1/k	WB,E	2; 3; 8; 10; 14-16; 19

Overview available clones for licensing page 2

Name	Clones	Host	Reactivity	Isotype	Application	References
C3a/C3a(desArg)	Z22/8	mouse	porcine	IgG2b/k	WB,E,IP, FN	3; 17;18
	K5/9	mouse	porcine	IgG1/k	WB, E, FN	3; 17;18
C5a/C5a (desArg)	T13/9	mouse	porcine	IgG1/k	WB,E,IP, FN	3; 17;18
Complementreceptor C5aR (CD88)	P12/1	mouse	human	IgG1/k	WB, F, IH	20
	S5/1	mouse	human	IgG2a/k	WB, F, E, FN, IP, blocking	20
	W17/1	mouse	human	IgG1/k	F,E	20
	R63	mouse	rat	IgG1/k	F,IH	21
Phospho-C5aR/CD88 (Ser-334)	32G-1	mouse	human	IgG1/k	WB, IF, E20	42
Chemokine receptor CCR5	R22/7	mouse	human		IF, FC, WB	22
	T21/8	mouse	human		IF, FC, WB, IP, E	22
	E11/19	mouse	human		IF, WB, E	22
Phospho CCR5 (Ser- 337)	V14/2	mouse	human		I, WB, E	22
Nonphospho-CCR5 (Ser 337)	RC-10	mouse	human		IF, WB, E	22
	R22/7	mouse	human		IF, FC, WB	22
Chemokine receptor CCR7	4B12	rat	mouse	IgG2a	IP, F	23; 24
Complementreceptor C3aR	hC3aRZ8 (clone17)	mouse	human	IgG2b	F, IH	25; 26
	hC3aRZ3 (clone76)	mouse	human	IgG2b	FI	27;28

Overview available clones for licensing page 3

Name	Clones	Host	Reactivity	Isotype	Application	References
	74	mouse	rat		F, IH	29
	IG4	rat	mouse	IgG1/k	F, IH	26
	14D4	rat	mouse	IgG2a	F, IH	26
Complementreceptor C5aR	20/70	rat	mouse	IgG2b	F, Blocking	30;31;32
	10/92	rat	mouse	IgG2a	F, IH	31
	8D6	rat	human	IgG2a	F, IH, Blocking	not yet published
	15C4	rat	human	IgG2a	F, IH, Blocking	not yet published
Beta-arrestin1 and Beta-arrestin2	25G10	mouse	human, rat, hamster beta-arrestin1	IgG1/k	WB, IP	not yet published
	21B1	mouse	human, rat, hamster beta-arrestin1 and beta-arrestin2	Ig1/k	WB, IP	44
Chemokine receptor CCR9	9B1	rat	mouse	IgG2a/k	F	33
Interleukin 8	SE2	mouse	human	IgG2b/k	F, WB, IH	34
	HC2	mouse	human	IgG1/k	F, WB IH	34
Complementfactor H	IH10	mouse	human	IgG1/k	IB, ELISA	not yet published
	23F8	mouse	human	IgG1/k	IB, ELISA	not yet published
Beta2-adrenergic receptor	13D6	mouse	human	IgG1/k	IB, IP, IF, F	not yet published
	R11E1	mouse	human	IgG1/k	IB, IP, IF, F	43

Overview available clones for licensing page 4

Name	Clones	Host	Reactivity	Isotype	Application	References
PIWIL2	87/3	mouse	human	IgM	IH, ELISA	not yet published
Pox Viruses	BCoV1/1	mouse	bovine coronavirus; human coronavirus	IgG1	E; IF; VN	35
	FPXV-8F3	mouse	Fowlpoxvirus, Turkeypoxvirus	IgG3/k	E, IF, IB, IP, IGEM, NVN	36
	FPXV-3D9	mouse	Fowlpoxvirus, Turkeypoxvirus	IgG1	E, IF, IB, IP, IGEM, NVN	36;37
	VACV-5B4	mouse	All orthopoxviruses without ectomelia and monkeypox	IgG2a	E, IF, IB, IP, F, IGEM, VN	38;39;40
	VACV-5C7	mouse	Monkeypoxvirus and other orthopoxviruses	IgG1	E, IF, IB, IP, IGEM, NVN	39
	PPV-4D9	mouse	All Parapoxviruses	IgM	E, IF, IB, IP, F, IGEM, VN	41
	CNPV-5A11	mouse	Canarypox virus	IgG2a/k	E, IF, IB, IP, IGEM, NVN	37
	VACV-5B1	mouse	All orthopoxviruses	IgG2a	E, IF, IB, IP, F, IGEM, NVN	39
AP-Tag / Avitag	EF10	mouse	human	IgG1/k	E, IF, F, FN	45
Nanobodies						
Synthaxin 1a	stx1a- Nb2_K81	alpaca	rat	heavy chain IgG	IF, IB, E	in preparation
SNAP25	S25-G1- D10	alpaca	rat	heavy chain IgG	IF, IB, E	in preparation

E: ELISA; IF: Immunofluorescence; IB: Immunoblotting; IP: Immunoprecipitation; IGEM: Immunogold electron microscopy; IH: Immunohistochemistry; F: Flow cytometry; FN: Functional studies; NVN: not virus neutralizing; VN: virus neutralizing; WB: Western blotting

Reference List for monoclonal antibodies mAB

1. Oppermann, M., Baumgarten, H., Brandt, E., Gottsleben, W., Kurts, C., and Götze, O. (1990) *J. Immunol. Methods***133**, 181-1902.
2. Oppermann, M., Kurts, C., Zierz, R., Quentin, E., Weber, M. H., and Götze, O. (1991) *Kidney Int.***40**, 939-947.
3. Oppermann, M., Höpken, U., and Götze, O. (1992) *Immunopharm.***24**, 119-134
4. Oppermann, M. and Götze, O. (1994) *Mol. Immunol.***31**, 307-314
5. Kaiser, J., Oppermann, M., Götze, O., Deppisch, R., Göhl, H., Asmus, G., Röhrich, B., von Herrath, D., and Schäfer, K. (1994) Significant reduction of factor D and immunosuppressive complement fragment Ba by haemofiltration.
6. Würzner, R., Schuff-Werner, P., Franzke, A., Nitze, R., Oppermann, M., Armstrong, V. W., Eisenhauer, T., Seidel, D., and Götze, O. (1991) *Eur. J. Clin. Invest.***21**, 288-294.
7. Schuff-Werner, P., Schütz, E., Reitemeyer, F., Oppermann, M., Eisenhauer, T., Armstrong, V., Köstering, H., Götze, O., and Seidel, D. (1990) Heparin-induced extracorporeal LDL-precipitation (HELP): rheological, hemostaseological and immunological effects. In Gotto, A. M., Mancini, M., Richter, W. O., and Schwandt, P., editors. *Treatment of severe hypercholesterolemia in the prevention of coronary heart disease*, Basel, Karger
8. Oppermann, M., Haubitz, M., Quentin, E., and Götze, O. (1988) *Klin. Wochenschr.***66**, 857-864
9. Püschel, G. P., Oppermann, M., Muschol, W., Götze, O., and Jungermann, K. (1989) *FEBS Lett.***243**, 83-87
10. Nezlin, R., Freywald, A., and Oppermann, M. (1993) *Mol. Immunol.***30**, 935-940
11. Püschel, G. P., Hespeling, U., Oppermann, M., and Dieter, P. (1993) *Hepatology***18**, 1516-1521
12. Elsner, J., Oppermann, M., Czech, W., Dobos, G., Schöpf, E., Norgauer, J., and Kapp, A. (1994) C3a activates oxygen radical species production and intracellular calcium transients in human eosinophils.
13. Elsner, J., Oppermann, M., Czech, W., Schöpf, E., and Kapp, A. (1994) *Blood***83**, 3324-3331.
14. Ammon, H. P. T., Ege, W., Oppermann, M., Göpel, W., and Eisele, S. (1995) *Anal. Chem.***67**, 466-471
15. Püschel, G. P., Dieter, P., Muschol, W., Oppermann, M., Hülsmann, M., Schulze-Specking, A., Götze, O., Decker, K., and Jungermann, K. (1991) Prostanoid production in Kupffer cells: A step in the increase in glucose and lactate output and reduction of flow by anaphylatoxins in perfused rat liver. In Wisse, E., Knook, D. L., and Decker, K., editors. *Cells of the hepatic sinusoid*, Leiden, Kupffer Cell Foundation
16. Lhotta, K., Würzner, R., Kronenberg, F., Oppermann, M., and König, P. (1998) *Kidney Int.***53**, 1044-1051
17. Höpken, U., Strüber, A., Oppermann, M., Mohr, M., Mücke, K. H., Burchardi, H., and Götze, O. (1993), Production and characterization of peptide-specific monoclonal antibodies that recognize a neoepitope on hog C5a. In Faist, E., Meakins, J., and Schildberg, F. W., editors. *Host defense dysfunction in trauma, shock and sepsis*, Berlin, Heidelberg, Springer Verlag.
18. Höpken, U., Mohr, M., Struber, A., Montz, H., Burchardi, H., Götze, O., and Oppermann, M. (1996) *Eur. J. Immunol.***26**, 1103-1109
19. Oppermann, M., Schulze, M., Götze, O. (1991) A sensitive enzyme immunoassay for the quantitation of human C5a/C5a(desArg) anaphylatoxin using monoclonal antibody with specificity for a neotope. *Complement Inflamm.* **8** (1):13-24
20. Oppermann et al, *J. Immunol.* 1993, **151**:3785-95
21. Schlaf et al, *Lab Invest.***79**:1287-97
22. Pollok-Kopp, B. et al., *J. Biol. Chem.* 2003 **278**:2190
23. Ohl, L. et al., (2004) *Immunity***21**:279-88
24. Ritter, U. Et al., (2004) *J. Leukoc Biol.*, **76**:472-476
25. Soruri, A., Kiafard, Z., Dettmer, C., Riggert, J., Kohl, J., Zwirner, J., (2003), IL-4 down-regulates anaphylatoxin receptors in monocytes and dendritic cells and impairs anaphylatoxin-induced migration in

- vivo. *J. Immunol.* **170**:3306–3314
26. Kiafard, Z., Tschernig, T., Schweyer, S., Bley, A., Neumann, D., Zwirner, J., (2007), Use of monoclonal antibodies to assess expression of anaphylatoxin receptors in tubular epithelial cells of human, murine and rat kidneys. *Immunobiology*, **212**:129–139
 27. Werfel, T., Kirchhoff K, Wittmann M, Begemann G, Kapp A, Heidenreich F, Götze O, Zwirner J., (2000) *J Immunol.*, **165**:6599-605.
 28. Zwirner, J., Götze O, Begemann G, Kapp A, Kirchhoff K, Werfel T., (1999), *Immunology.*, **97**:166-72
 29. Luhmann, A.E., et al., 2001, *Mol Immunol*, **38**: 108 (Abstract)
 30. Godau, J. Et al., (2004), *J of Immunol.*, **173**(5): 3437-45
 31. Soruri, A. et al., (2003), **88**: 47-52
 32. Shushakova, N. et al, (2002), *Journal Clin Invest*, **110**: 1823-30
 33. Rivera-Nieves J, Ho J, Bamias G, Ivashkina N, Ley K, Oppermann M, Cominelli F. (2006), *Gastroenterology*. **131** (5):1518-29
 34. Zahn, S., Zwirner, J., Spengler, H.P., Götze, O. (1997), *Eur J Immunol*, **27**(4): 935-40
 35. Czerny, C.-P., Eichhorn, W. (1989): Characterization of monoclonal and polyclonal antibodies to bovine enteric coronavirus, establishment of an efficient ELISA for antigen detection in feces. *Vet.Microbiol.***20**: 111-122
 36. Boulanger, D., Green, Smith, T., Czerny, C.-P., Skinner, M.A. (1998): The 131-amino-acid repeat region of the essential 39-kilodalton core protein of fowlpox virus FP9, equivalent to vaccinia virus A4L protein, is non-essential and highly immunogenic. *J.Virol.***72**: 170-179
 37. Isa, G., Pfister, K., Kaaden, O.-R., Czerny, C.-P. (2002): Development of a monoclonal blocking ELISA for the detection of antibodies against fowlpox virus. *J.Vet.Med.B.***49**: 21-23.
 38. Czerny, C.-P., Mahnel, H. (1990): Structural und functional analysis of orthopox virus epitopes. *J.Gen.Virol.*, **71**: 2341-2352.
 39. Czerny, C.-P., Johann, S., Hölzle, H., Meyer, H. (1994): Epitope detection in the envelope of intracellular naked orthopox viruses and identification of their encoding genes. *Virology***200**: 764-777.
 40. Meyer, H., Osterrieder, N., Czerny, C.-P. (1994): Identification of binding sites for neutralizing monoclonal antibodies on the 14 kDa fusion protein of different orthopox virus species. *Virology***200**: 778-783.
 41. Czerny, C.-P., Waldmann, R., Scheubeck, T. (1997): Identification of three different antigenic sites in parapox viruses. *Arch.Virol.***142**: 807-821.
 42. Pollok-Kopp B., Hüttenrauch, F., Rethorn, S., Oppermann, M., *J. Biol. Chem.* (2007) 282:4345
 43. Huang, C. et al. *J. Biol. Chem.* (2009) 284:17206
 44. Hüttenrauch, F. et. al. (2005) *J. Biol. Chem.* 280:37503
 45. Liebick M., Schläger C., Oppermann M. (2016) Analysis of Chemokine Receptor Trafficking by Site-Specific Biotinylation. *PLoSOne***11** (6):e0157502.

Contact

Dipl.-Biol. Christiane Bolli
 Licensing Manager Research Materials
 E-Mail: cbolli@sciencebridge.de
 Tel.: +49 551 30724 156